Fresenius SE & Co. KGaA
- ISIN DE0005785604
- Country Deutschland
Company profile
Fresenius is a global healthcare group offering high-quality products and services for dialysis, hospitals, and outpatient treatment. With over 300,000 employees in more than 100 countries around the globe, and annual sales exceeding €35 billion, Fresenius is one of the world’s leading healthcare companies.
Management
Michael Sen
Chairman of the Management Board
Michael Sen, 55, became Chairman of the Management Board of Fresenius (equivalent to President and CEO) on October 1, 2022. He joined Fresenius in April 2021 as Chairman of the Management Board of Fresenius Kabi. Before joining Fresenius Kabi, Michael Sen was a member of the Management Board of Siemens AG, where he was responsible for the healthcare business Siemens Healthineers and for Siemens’ energy business. Prior to that, he was Chief Financial Officer of E.ON SE. At the start of his professional career, Michael Sen completed an apprenticeship at Siemens in Berlin and then studied business administration at the Technical University of Berlin.
Download CV
Download CV
Pierluigi Antonelli
CEO Fresenius Kabi
Pierluigi Antonelli, 56, joined the Management Board of Fresenius in March 2023 with responsibility for Fresenius Kabi. In his previous role since 2019, he was the CEO of Angelini Pharma, a company of the Italian Angelini Group specializing in brain health and consumer health. Prior to that, he held senior leadership positions at Novartis Oncology, Sandoz, Merck & Co. and Bristol Myers Squibb in the United States and across Europe.
Download CV
Download CV
Sara Hennicken
Chief Financial Officer
Sara Hennicken (43) was appointed CFO of Fresenius as of September 1, 2022. She joined the Group in 2019 as Senior Vice President Global Treasury & Corporate Finance for Fresenius and Fresenius Medical Care. Previously, she spent 14 years in investment banking, including nine years at Deutsche Bank, lastly as Managing Director and Senior Client Executive in Corporate Finance Coverage before moving to Fresenius. Between 2005 and 2010 she worked for Citigroup in Frankfurt and London. Sara Hennicken studied economics in Germany and in the United States.
Download CV
Download CV
Robert Möller
CEO Fresenius Helios
Robert Möller, 56, joined the Management Board of Fresenius in September 2023 with responsibility for Fresenius Helios. Robert Möller has been CEO of Helios Kliniken GmbH since 2022. He joined Helios in 2014, where he held the position of Clinic Managing Director at Helios Hanseklinikum Stralsund until 2017. After a short time away, he returned to Helios in 2019 and took over the management of various regions. Möller studied human medicine at the University of Hamburg and practiced as a specialist for internal medicine. After various medical positions and a part-time master’s degree in health care management, he switched to hospital management while continuing to work as a physician.
Download CV
Download CV
Michael Moser
Legal, Compliance, Risk Management, ESG, Human Resources and Fresenius Vamed
Michael Moser (47) joined the Management Board of Fresenius in July 2023 with responsibility for Legal, Compliance, Risk Management, ESG and the business segment Fresenius Vamed. Since December 2023, he is also responsible for Human Resources. After starting his career at Baker McKenzie, he joined E.ON SE in 2008. During this time, he inter alia became member of the Management Board of the stock listed company ENEVA in Brazil, steered the listing of Uniper and served as Deputy CEO and CFO of Enerjisa, the stock listed leading energy company in Turkey. He has received university degrees in law and business economics in Germany, USA, UK, Switzerland and China.
Download CV
Download CV
Latest News
IR contact
Fresenius SE & Co. KGaA
Investor Relations
Else-Kröner-Straße 1
D-61352 Bad Homburg
T: +49 (0) 6172 608-2485
F: +49 (0) 6172 608-2488
ir-fre@fresenius.com
Postal address:
Fresenius SE & Co. KGaA
Investor Relations
D-61346 Bad Homburg v.d.H.
Markus Georgi
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-2485
Florian Feick
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0 6172 608-5167
Elisabeth Truckenbrodt
Director Investor Relations
T: +49 (0) 6172 608-2486
elisabeth.truckenbrodt@fresenius.com
